Similarly, the PARPi olaparib has been combined with the α-selective PI3K inhibitor alpelisib in a Phase 1b study of recurrent triple-negative or germline BRCA1 and BRCA2-mutated breast cancer [46]. Here, BRCA1 is linked to breast cancer.